

## To: The Copenhagen Stock Exchange

### Announcement no. 12 • 2005/06 January 19, 2006

# Q1 interim report for the three months ended November 30, 2005

#### Financial performance in Q1

- Revenue was DKK 417 million (325), representing an increase of 28%, of which organic growth accounted for 14%.
- EBIT for the core business was DKK 126 million (81), representing a 56% increase.
- Pipeline costs amounted to DKK 51 million (41).
- Consolidated EBIT was DKK 75 million DKK (40).
- EBT was DKK 97 million (27).

#### Highlights of the period

- At the annual general meeting held on December 13, a resolution was passed to merge Chr. Hansen Holding A/S and ALK-Abelló A/S with ALK-Abelló A/S as the continuing company listed on the Copenhagen Stock Exchange.
- ALK-Abelló is taking over Schering's 50% interest in the subsidiary ALK-Scherax with effect from January 2006, which will make the company a wholly-owned subsidiary of ALK-Abelló.

#### Outlook for the 2005/06 financial year

 The results for the period are in line with the latest forecasts made in the 2004/05 annual report. The forecast of revenue for the 2005/06 financial year remains unchanged at approximately DKK 1.5 billion, with organic growth in the range of 8-10%. After pipeline costs of approximately DKK 200 million and costs associated with the launch of GRAZAX<sup>®</sup>, the company retains its forecast of EBIT at DKK 35-55 million. As a result of higher interest income, the forecast for ordinary profit before tax (EBT) is now DKK 55-75 million, up from the previous figure of DKK 45-65 million.

> Hørsholm, January 19, 2006 ALK-Abelló A/S

Jørgen Worning Chairman of the Board of Directors Jens Bager President and CEO

#### Contact:

Jens Bager, President and CEO, tel +45 4574 7445.

ALK-Abelló will hold a conference call for analysts and investors today at 3.30 p.m. (CET) at which Jens Bager, President and CEO, will review the results. Danish participants must call in on tel +45 7026 5040 before 3.25 p.m. (CET), and international participants must call in on tel +44 207 769 6432 before 3.25 (CET). The conference call will also be webcast on our website: www.alk-abello-investor.com, where the related presentation will be available shortly before the conference call begins.



## FINANCIAL HIGHLIGHTS AND KEY RATIOS (unaudited)

Effective September 1, 2005, the company's accounting policies, including the presentation of the financial statements, were changed to be in accordance with the International Financial Reporting Standards (IFRS/IAS). The changes were described in the 2004/05 annual report. The effects of the discontinuation of the ingredients business are stated as a separate line item in the income statement. In order to ensure full comparability, the financial figures and information for 2004/05 have been restated to IFRS/IAS.

DKKm	Q1 2005/06	Q1 2004/05	Full year 2004/05
Income statement			
Revenue	417	325	1,217
Operating profit (EBIT)	75	40	2
Net financial items	22	(13)	(68)
Profit before tax (EBT)	97	27	(66)
Net profit/(loss), continuing operations	59	13	(68)
Net profit, discontinuing operations	-	67	4,416
Net profit	59	80	4,348
EBIT margin - %	18.0	12.3	0.2
Average number of employees	1,207	1,005	1,027
Balance sheet			
Total assets	2,950	5,181	6,915
Invested capital	625	4,053	594
Equity	2,283	1,983	6,208
	,		,
Cash flow and investments			
Cash flow from operating activities	33	138	407
Cash flow from investing activities	(14)	(41)	5,938
Free cash flow	19	97	6,345
Information on shares			
Dividend	-	-	4,050
Share capital	101	101	101
Shares in thousands of DKK 10 each	10,128	10,128	10,128
Share price - DKK	584	639	951
Net asset value per share - DKK	221	191	611
Key figures			
ROAIC - %	12.3	3.7	15.1
		0.5	404.0
Earnings per share (EPS) - DKK	4.2	6.5	424.8
Earnings per share (EPS), continuing operations - DKK	4.2	(0.1)	(10.6)
Cash flow per share (CFPS) - DKK	3.3	13.6	40.2
Price earnings ratio (PE)	138	98	2
Share price/Net asset value	2.6	3.3	1.6
Devenue growth			
Revenue growth   Organic growth	14	5	6
Exchange differences	14	(1)	(1)
Acquisitions	- 14	(')	(')
Divestments	14	-	(7)
Total growth - %	- 28	4	(7)
	20	7	(2)

Definitions: see last page




INCOME STATEMENT (by the quarter)				
	Q1		Q1	
DKKm	2005/06	%	2004/05	%
Revenue	417	100	325	100
Cost of sales	128	31	103	32
Gross profit	289	69	222	68
Research and development expenses	63	15	52	16
Sales, marketing and administrative expenses	151	36	118	36
Operating profit before special items	75	18	52	16
Settlement of share options	-	0	12	4
Operating profit (EBIT)	75	18	40	12
Interest income and other financial income	26	6	2	1
Interest expenses and other financial expenses	4	1	15	5
Profit before tax (EBT)	97	23	27	8
Tax on profit	38	9	14	4
Net profit, continuing operations	59	14	13	4


## **FINANCIAL REVIEW**

The ALK-Abelló Group posted **revenue** of DKK 417 million (325) for the period, equivalent to an increase of 28%. Adjusted for the June 2005 acquisition of French-based company Allerbio, the rate of organic growth was 14% (5%). Exchange rates did not generally affect revenue.

The reduction of the mandatory discount in Germany on January 1, 2005 from 16% to 6% had a favourable effect on growth in Q1 2005/06.



The growth in revenue was mainly attributable to the southern European region, which recorded 89% growth, primarily due to the effect of the Allerbio acquisition. Revenue in the northern European region rose by 32%, mostly as a result of growing EpiPen<sup>®</sup> sales.



Sales of allergy vaccines accounted for 81% (83) of revenue, whilst diagnostic products, EpiPen<sup>®</sup> and other trading goods accounted for the remaining sales. The drop-based products (SLIT) accounted for 31% (21%) of total allergy vaccine sales.



Eliminating the favourable effect of the Allerbio acquisition, revenue from the SLIT products continued to grow at a higher rate than revenue from injection-based products (SCIT).

**Cost of sales** amounted to DKK 128 million (103), which brought **gross profit** up to DKK 289 million (222). The gross margin rose to 69% (68%).

**Research and development costs** for the period totalled DKK 63 million (52), equivalent to 15% of revenue. **Capacity costs** reached a total of DKK 214 million (170) as a result of the Allerbio acquisition and increased sales and marketing activities.

EBIT	Q1	Q1
DKKm	2005/06	2004/05
Core business	126	81
Pipeline	(51)	(41)
EBIT	75	40
EBIT % of sales	18%	12%

**EBIT for the core business** was DKK 126 million (81), whilst **pipeline costs** amounted to DKK 51 million (41). Most of the pipeline costs are used for pharmaceutical development, clinical studies and registration of new vaccines. This brought **consolidated EBIT** to DKK 75 million DKK (40).

**Profit before tax (EBT)** was DKK 97 million (27), and the increase over last year's EBT was attributable to rising earnings and higher net financials.

**Income tax** amounted to DKK 38 million, corresponding to an effective tax rate of 39%, and **consolidated profit** of the ALK-Abelló Group was DKK 59 million (13).

**Equity** stood at DKK 6,208 million at the beginning of the period. The interim dividend of DKK 4 billion distributed in October reduced equity significantly, to DKK 2,283 million at the end of the period.

### **Transition to IFRS/IAS**

As stated in the 2004/05 annual report, the consolidated interim and annual reports of the ALK-Abelló Group will be presented according to the International Financial Reporting Standards (IFRS) as from the current financial year.

Thus this interim report is presented in accordance with the recognition and measurement provisions of IFRS as well as Danish disclosure requirements for interim financial reporting for listed companies. See also the annex on page 14 of this announcement.

The 2004/05 annual report lists the areas within the consolidated financial statements of the ALK-Abelló Group that are affected and how the changes are reflected in the figures presented. For further details, we therefore refer to the 2004/05 annual report.

#### Outlook for the 2005/06 financial year

The results in this interim report are in line with the latest forecasts made in the 2004/05 annual report.

The costs of launching GRAZAX<sup>®</sup> are expected to have a significant impact on operating costs for the rest of the year.

On this basis, the forecast of revenue for the 2005/06 financial year remains unchanged at approximately DKK 1.5 billion, with organic growth in the range of 8-10%. After pipeline costs of approximately DKK 200 million and costs associated with the launch of GRAZAX<sup>®</sup>, the company retains its forecast of EBIT at DKK 35-55 million. As a result of higher interest income, the forecast for ordinary profit before tax (EBT) is now DKK 55-75 million, up from the previous figure of DKK 45-65 million.



#### **OPERATING REVIEW**

#### Allergy research center opened in China

In September 2005, ALK-Abelló opened an allergy research center in China. The center will focus on the causes of allergy in China, where house dust mite allergy is the most widespread type.

#### GT-08: Clinical study of GRAZAX<sup>®</sup>

In October 2005, ALK-Abelló published the results of the GT-08 study of GRAZAX<sup>®</sup>, the company's tablet-based vaccine against grass pollen allergy.

The GT-08 study, which involved 634 patients with grass pollen allergy, showed that, on average, GRAZAX<sup>®</sup> reduces patients' symptoms of hay fever by 30% (median value 34%) and reduces the need for symptom-relieving medication by 38% (median value 53%) in addition to the placebo effect.

The GT-08 study will continue over the next few years in order to document the beneficial long-term effect of Grazax<sup>®</sup>. The GT-08 results have been submitted to the Swedish regulatory authorities, and the application for registration is still pending. ALK-Abelló still expects to be able to launch GRAZAX<sup>®</sup> on the first European markets in late 2006.

# Tolerability study of tablet to treat house dust mite allergy

ALK-Abelló has completed the clinical part of the first tolerability study (Phases I/IIa) of the company's tablet-based vaccine against house dust mite allergy.

The results of the study are currently being analyzed and are expected to form the basis for a combined dosis/effect study (MT-02).

#### Full ownership of German sales subsidiary

ALK-Abelló A/S expects to take over Schering AG's 50% interest in the German-based sales subsidiary ALK-Scherax with effect from January 2006. The agreed purchase price will be EUR 35-40 million (DKK 265-300 million).

For strategic reasons, ALK-Abelló will be taking over ALK-Scherax as a wholly-owned subsidiary earlier than originally intended, as ALK-Abelló considers the German market very important to its sales and marketing of existing and future products in Europe – not least in connection with the expected launch of GRAZAX<sup>®</sup>.

As previously mentioned, the ALK-Abelló Group will present its financial statements in accordance with the International Financial Reporting Standards IFRS/IAS as from the current financial year. Under these standards, the acquisition will have no direct impact on profit as goodwill will not be amortized and as profit attributable to minority interests will no longer be stated as a cost in the income statement but as a line item under the statement of profit allocation.

#### ALK-Abelló A/S now the listed company

At the company's annual general meeting held on December 13, 2005, a resolution was passed to merge ALK-Abelló A/S and Chr. Hansen Holding A/S with ALK-Abelló A/S as the continuing, listed company. The merger has effect from September 1, 2005.

In addition, a resolution was passed authorizing the Board of Directors to declare an extraordinary dividend if ALK-Abelló's financial position and plans provide a basis for such a distribution.

On December 23, the name change was registered by the Copenhagen Stock Exchange, where ALK-Abelló A/S is now listed under the new securities identification code/ISIN DK0060027142 and the symbol ALK B.

#### **Capital base**

The Board of Directors and Board of Management have initiated a reassessment of the company's strategic plans and future capital structure, which is expected to be completed in the second half of the 2005/06 financial year.



#### **Financial calendar**

Silent period: April 3, 2006 H1 interim report (Q2) 2005/06: April 24, 2006 Silent period: June 13, 2006 Nine-month interim report (Q3) 2005/06: July 4, 2006 Silent period: Week 44, 2006 Annual report 2005/06: Week 47, 2006

In compliance with the rules of the Copenhagen Stock Exchange, ALK-Abelló A/S has introduced a three-week silent period ahead of the release of interim reports. During the silent period, communication with analysts, the business press, shareholders, investors, etc. is restricted.

#### Forward-looking statements

This interim report contains forward-looking statements, including forecasts of future revenue and future operating profit. Such statements are subject to risks and uncertainties as various factors, many of which are beyond the control of the ALK-Abelló Group, may cause actual results and performance to differ materially from the forecasts made in this interim report. Factors that might affect such expectations include, among others, overall economic and business conditions, fluctuations in currencies, demand and competitive factors. This interim report has been translated from Danish into English. However, the Danish text shall be the governing text for all purposes, and in case of any discrepancy the Danish wording shall be applicable.



### STATEMENT BY THE MANAGEMENT

The Board of Directors and Board of Management today considered and adopted the Q1 interim report of ALK-Abelló A/S for the three months ended November 30, 2005.

The interim report is presented in accordance with the provisions on recognition and measurement set out in the International Financial Reporting Standards (IFRS/IAS), Danish accounting legislation and the Copenhagen Stock Exchange interim reporting requirements for listed companies. As in previous years, the interim report is unaudited.

We consider the accounting policies to be appropriate. Accordingly, the interim report gives a true and fair view of the Group's financial position, results of operations and consolidated cash flows.

Hørsholm, January 19, 2006

#### **Board of Management**

Jens Bager (President & CEO)	Jutta af Rosenborg	Anders Hedegaard
Henrik Jacobi	Flemming Steen Jensen	
Board of Directors		
Jørgen Worning (Chairman)	Thorleif Krarup (Vice Chairman)	Nils Axelsen
Carsten Lønfeldt	Jesper Fromberg Nielsen	Anders Gersel Pedersen
Ingelise Saunders	Peter Adler Würtzen	



### INCOME STATEMENT

September 1 - November 30

		Q1	Q1
Note	DKKm	2005/06	2004/05
1	Revenue	417	325
	Cost of sales	128	103
	Gross profit	289	222
	Research and development expenses	63	52
	Sales and marketing expenses	112	82
	Administrative expenses	39	37
	Other operating income	-	1
	Other operating expenses	_	-
	Operating profit before special items	75	52
	Settlement of share options	-	12
	Operating profit (EBIT)	75	40
	Internet in a second all second second second		0
	Interest income and other financial income	26	2
	Interest expenses and other financial expenses	4	15
	Profit before tax (EBT)	97	27
	Tax on profit	38	14
	Net profit, continuing operations	59	13
2	Net profit, discontinued operations		67
2		- 59	67
	Net profit	59	80
	Attributable to:		
	Equity holders of the parent	43	66
	Minority interests	16	14
		59	80
	Forningo per choro (EDC)	4.2	6 F
	Earnings per share (EPS) - DKK	4.2	6.5
	Earnings per share (EPS), continuing operations - DKK	4.2	(0.1)



# CASH FLOW STATEMENT

September 1 - November 30

	Q1	Q1
DKKm	2005/06	2004/05
Operating profit	59	80
Adjustments:		
Tax on profit	38	43
Interest income and expenses	(22)	31
Settlement of share options	-	13
Depreciation, amortization and write-downs	15	58
Change in provisions	2	(4)
Net interest paid	22	(31)
Income taxes paid	(18)	(22)
Cash flow before change in working capital	96	168
Change in inventories	13	(14)
Change in receivables	(5)	(3)
Change in short-term payables	(71)	(13)
Cash flow from operating activities	33	138
Additions, intangible assets	(5)	_
Additions, property, plant and equipment	(3)	(53)
Sale of intangible assets and property, plant and equipment	(3)	(33)
Change in other non-current financial assets	-	1
Cash flow from investing activities	(14)	(41)
Free cook flow	40	07
Free cash flow	19	97
Dividend paid to equity holders of the parent	(3,996)	-
Dividend paid to minority interests	-	(1)
Sale of treasury shares	11	-
Change in financial liabilities	(2)	(46)
Cash flow from financing activities	(3,987)	(47)
Net cash flow	(3,968)	50
-	(-,•)	
Cash and cash equivalents at September 1	5,540	123
Unrealized gain on foreign currency carried as cash		
and cash equivalents	-	1
Net cash flow	(3,968)	50
Cash and cash equivalents at November 30	1,572	174

The cash flow statement has been adjusted to the effect that exchange rate adjustments in foreign subsidiaries are not included in the statement. As a result, the individual figures in the cash flow statement cannot be reconciled directly to the income statement and balance sheet.



#### BALANCE SHEET ASSETS

DKKm	Nov. 30 2005	Aug. 31 2005	Nov. 30 2004
Non-current assets			
Land and buildings	252	253	1,130
Plant and machinery	141	142	590
Other fixtures and equipment	42	41	142
Property, plant and equipment in progress	78	76	204
Goodwill	113	112	830
Other intangible assets	75	75	208
Securities and receivables	9	9	10
Deferred tax assets	159	150	117
Total non-current assets	869	858	3,231
Current assets			
Inventories	285	298	927
Trade receivables	195	179	712
Income tax receivables	7	5	38
Other receivables	10	21	71
Prepayments	12	14	28
Cash and cash equivalents	1,572	5,540	174
Total currents assets	2,081	6,057	1,950
Total assets	2,950	6,915	5,181



#### BALANCE SHEET EQUITY AND LIABILITIES

DKKm	Nov. 30 2005	Aug. 31 2005	Nov. 30 2004
Equity			
Share capital	101	101	101
Other reserves	2,081	2,022	1,806
Proposed dividend	50	4,050	20
Equity attributable to equity holders of the parent	2,232	6,173	1,927
Minority interests	51	35	56
Total equity	2,283	6,208	1,983
Non-current liabilities			
Mortgage debt	33	28	335
Bank loans and financial loans	41	42	1,508
Pensions and similar liabilities	51	50	76
Deferred tax	-	-	55
Other provisions	148	147	69
Other payables	17	16	1
	290	283	2,044
Current liabilities			
Mortgage debt	1	8	56
Bank loans and financial loans	7	7	417
Trade payables	108	148	248
Income taxes	64	33	71
Other payables	169	203	307
Deferred income	28	25	55
	377	424	1,154
Total liabilities	667	707	3,198
Total equity and liabilities	2,950	6,915	5,181



#### EQUITY

DKKm	Share capital	Other reserves	Proposed dividend	Equity holders of the parent	Minority	Total equity
DKKIII	capitai	reserves	aividend	the parent	meresis	equity
Equity at September 1, 2005	101	2,019	4,050	6,170	-	6,170
Effect of changes in accounting policies		3		3	35	38
Equity at September 1, 2005 (restated)	101	2,022	4,050	6,173	35	6,208
Net profit		43		43	16	59
Foreign currency translation adjustment of foreign						
subsidiaries		1		1		1
Total recognized income and expenses	-	44	-	44	16	60
Sale of treasury shares		11		11		11
Dividend paid		4	(4,000)	(3,996)		(3,996)
Equity at November 30, 2005	101	2,081	50	2,232	51	2,283
Equity at September 1, 2004	101	1,781	20	1,902	-	1,902
Effect of changes in accounting policies		(3)		(3)	43	40
Equity at September 1, 2004 (restated)	101	1,778	20	1,899	43	1,942
Net profit		27		27	14	41
Adjustment regarding share options		1		1		1
Foreign currency translation adjustment of foreign subsidiaries						-
Total recognized income and expenses	-	28	-	28	14	42
Dividend paid					(1)	(1)
Equity at November 30, 2004	101	1,806	20	1,927	56	1,983



	Q1	Q1
DKKm	2005/06	2004/05
1 REVENUE		
Geographical segments		
Northern Europe	74	56
Central Europe	182	170
Southern Europe	109	58
Other markets	52	41
Total	417	325
2 NET PROFIT, DISCONTINUED OPERATIONS		

#### Revenue 845 Cost of sales 503 \_ Gross profit 342 -Research and development expenses 57 Sales and marketing expenses 107 Administrative expenses 65 Other operating income 4 \_ 2 Other operating expenses \_ 115 Operating profit before special items -Settlement of share options -1 114 **Operating profit** -Gain on divestment -Interest income and other financial income 4 Interest expenses and other financial expenses 22 -Profit before tax 96 -Tax on profit 29 -67 Net profit -



#### RECONCILIATION OF INCOME STATEMENT AND EQUITY FOR 2004/05 FROM PREVIOUSLY APPLIED ACCOUNTING POLICIES TO IFRS/IAS

#### Accounting policies

Effective September 1, 2005, the accounting policies were changed in accordance with the International Financial Reporting Standards (IFRS/IAS). The transition date is September 1, 2004. The accounting policies applied in this interim report are the same as those applied in the 2004/05 annual report except for the changes described under "Transition to IFRS/IAS" in the annual report.

In the interim report, the presentation has been adjusted to IFRS/IAS (stated as "Adjustments" in the table below). In addition, the effect of the discontinuation of the ingredients business is isolated in a separate line item in the income statement (stated as "Reclassifications" in the table below).

		Q1 2004	4/05			Full year 2	004/05	
	Prior			IFRS/IAS	Prior			IFRS/IAS
	acct.	Reclassi-	Adjust-	acct.	acct.	Reclassi-	Adjust-	acct.
DKKm	policies	fications	ments	policies	policies	fications	ments	policies
Revenue	1,170	(845)		325	4,381	(3,164)		1,217
Cost of sales	606	(503)		103	2,345	(1,932)		413
Gross profit	564	(342)		222	2,036	(1,232)		804
Research and development expenses	108	(56)		52	442	(210)		232
Sales and marketing expenses	190	(108)		82	765	(407)		358
Administrative expenses	110	(73)		37	425	(259)	1	167
Other operating income	14	(13)		1	17	(16)		1
Other operating expenses	2	(2)		-	9	(9)		-
Operating profit before special items	168	(116)		52	412	(363)	(1)	48
Settlement of share options	-	-	12	12	46	-		46
Amortization of goodwill	16	(16)		-	59	(56)	(3)	-
Operating profit (EBIT)	152	(100)	(12)	40	307	(307)	2	2
Gain before tax from divestment	-	-		-	4,206	(4,206)		-
Interest income and other financial income	6	(4)		2	39	(24)		15
Interest expenses and other financial expenses	37	(22)		15	157	(74)		83
(Ordinary) profit/(loss) before tax (EBT)	121	(82)	(12)	27	4,395	(4,463)	2	(66)
Tax on (ordinary) profit	47	(29)	(4)	14	75	(73)		2
(Ordinary) profit/(loss) after tax	74	(53)	(8)	13	4,320	(4,390)	2	(68)
Extraordinary income after tax	-	-		-	14	(14)		-
Net profit, continuing operations	74	(53)	(8)	13	4,334	(4,404)	2	(68)
Net profit, discontinued operations	-	53	14	67	-	4,397	19	4,416
Net profit (including minority interests)	74	-	6	80	4,334	(7)	21	4,348
Minority interests' share of net profit	14	-	(14)	-	46	(7)	(39)	-
Net profit	60	-	20	80	4,288	-	60	4,348
Attributable to:								
Equity holders of the parent				66				4,302
Minority interest				14				46
				80				4,348
EQUITY	Ea	uity at Septer	nhor 1 20	04	=	quity at Augu	1et 31 2005	
	Prior	any at Septer	11001 1,20	IFRS/IAS	Prior	yuny at Augu	31,200	IFRS/IAS
	acct.	Reclassi-	Adjust-	acct.	acct.	Reclassi-	Adjust-	acct.
DKKm	policies	fications	ments	policies	policies	fications	ments	policies

policies	fications	ments	policies
1,902	-	40	1,942
Equ	uity at Novem	ber 30, 20	04
Prior			IFRS/IAS
acct.	Reclassi-	Adjust-	acct.
policies	fications	ments	policies

1,923

cies	policies	fications	ments	policies
942	6,170	-	38	6,208
/IAS				

Equity

60

1,983



Invested capital	Intangible assets, property, plant and equipment, inventories and receivables excluding provisions (deferred tax excluded), trade payables, other payables and minorities		
EBITA margin - %	Operating profit before amortization of goodwill x 100/Revenue		
EBIT margin - %	Operating profit x 100/Revenue		
Net asset value per share	Equity at end of period/Number of shares at end of period		
ROAIC - %	Return on average invested capital (Operating profit x 100/Average invested capital)		
Pay-out ratio - %	Dividend declared x 100/Net profit/(loss) for the period		
Earnings per share (EPS)	Net profit/(loss) for the period excluding extraordinary expenses/Average number of shares		
Cash flow per share (CFPS)	Cash flow from operating activities excluding minority shareholders' shares/Average number of shares		
Price earnings ratio (PE)	Share price/Earnings per share		
Equity ratio	Equity at end of period x 100/Equity and liabilities at end of period		
Segments	Geographical segments (based on subsidiaries' location): o Northern Europe comprises Nordic region, UK and the Netherlands o Central Europe comprises Germany, Austria and Switzerland o Southern Europe comprises Spain, Italy and France o Other markets comprise USA, China and rest of world		

Key figures are calculated in accordance with "Recommendations and Ratios 2005" issued by the Danish Society of Financial Analysts.